8th Heart in Diabetes
“Where the heart, kidney, and diabetes meet in clinical practice.”
June 7 -9, 2024 | Hilton Philadelphia at Penn's Landing
201 S. Christopher Columbus Blvd, Philadelphia, PA 19106
News & Meeting Coverage 2021
9/09/21 | Hybrid Heart in Diabetes conference highlights the intersection of cardiometabolic specialties
9/10/21 | SARS-CoV-2 has multifaceted CV involvement, unlike previous coronaviruses
9/10/21 | ‘Cultural competence’ key to reduced cardiometabolic risk among South Asian subgroups
9/11/21 | ‘All of us need to be vigilant: Steps to combat growing NAFLD, NASH epidemic
9/11/21 | Plant-based diets, and time-restricted eating provide cardiometabolic benefits
9/11/21 | Anti-arrhythmic effects of SGLT2 inhibitors 'may be an alias for improving heart failure
9/12/21 | Longer duration of diabetes, and prediabetes increase heart failure risk
9/12/21 | Time in the range — not HbA1c — should guide most diabetes treatment decisions
9/12/21 | Curiosity prevails: A conversation with Robert H. Eckel, MD
9/13/21 | Treatment of diabetic kidney disease ‘requires multiple drugs’
9/13/21 | Target young women with migraine for increased cardiovascular risk prevention
9/14/21 | Metabolic consequences of obstructive sleep apnea persist, despite treatment
HCPLive
9/10/21 | DARE-19 Shows SGLT2 Inhibitor Potential for Multi-Organ Protection
9/11/21 | Pam Taub, MD, FACC, FASPC: Progressive Dietary Measures for the Prevention of CVD
9/11/21 | Silvio Inzucchi, MD: Diversifying Treatments for Cardiovascular Events
9/11/21 | Pharmacological Strategies for Reduction of Obesity and CVD, Diabetes Risk
9/11/21 | Cardiovascular Disease and Racial Disparities Addressed in African American Patients
9/11/21 | Anti-Coagulants Recommended for Prevention of Atherosclerotic Cardiovascular Disease
9/11/21 | Type 2 Diabetes Risk Management Guidelines Are Not Reflected in US Practices
9/12/21 | Matthew Budoff, MD: Greater Adoption of SGLT2 Inhibitors and GLP-1 Agonists
9/12/21 | Potential Risks of CVD in Women with Polycystic Ovary Syndrome
9/12/21 | Theoretical Benefits of Continuous Glucose Monitoring on T2D Patients without Insulin
9/13/21 | Christie Ballantyne, MD: Promising Cardiovascular Agents in Diabetes
9/13/21 | Javed Butler, MD: Promising Heart Failure Trials and Guideline Limitations
9/14/21 | Christie Ballantyne, MD: Better Implementing Cardiovascular Research
9/15/21 | Yehuda Handelsman, MD: Organizing a Hybrid Cardiometabolic Meeting in 2021
9/22/21 | Laurence Sperling, MD, FACC, FACP, FAHA: Optimizing Cardiovascular Care
9/10/21 | Research Highlights Benefits of Aspirin, Monoclonal Antibody Use in Patients With Diabetes, COVID-19
9/10/21 | Presentation Outlines Long-term CV Risks of Gestational Diabetes
9/13/21 | Panel Outlines Updates on HF Treatment Developments, Recommendations for Guidelines
9/14/21 | Understanding Cardiovascular Risk in Polycystic Ovary Syndrome, With Andrea Dunaif, MD
9/14/21 | Silvio Inzucchi, MD: Stroke Prevention and Diabetes Medications
9/17/21 | Greater Adherence to Diabetes Guidelines Needed in US Medical Practices
9/15/21 | Matthew Budoff, MD: Need for Greater Uptake of Newer Medications
9/16/21 | Diabetes Medications and Stroke Prevention, With Silvio Inzucchi, MD
9/19/21 | ESC Prevention Guidelines, With Kausik Ray, MBChB, MD, MPhil